Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody

Jean-Marie Michot; Renaud Mazeron; Laurent Dercle; Samy Ammari; Charles Canova; Aurelien Marabelle; Shelonitda Rose; Eric Rubin; Eric Deutsch; Jean-Charles Soria; Vincent Ribrag; Antonin Levy

doi:10.1016/j.ejca.2016.06.017

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody

Eur J Cancer. 2016 Oct:66:91-4. doi: 10.1016/j.ejca.2016.06.017. Epub 2016 Aug 18.

Authors

Affiliations

¹ Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
² Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
³ Department of Nuclear Medicine, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
⁴ Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
⁵ Merck and Co., Inc., Rahway, NJ, USA.
⁶ Merck and Co., Inc., North Wales, PA, USA.
⁷ Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
⁸ Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
⁹ Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. Electronic address: [email protected].

PMID: 27544928
DOI: 10.1016/j.ejca.2016.06.017

No abstract available

Keywords: Abscopal effect; Hodgkin disease; Irradiation; Out-of-field; PD-1; Pembrolizumab.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carmustine / therapeutic use
Cytarabine / therapeutic use
Hodgkin Disease / drug therapy*
Hodgkin Disease / pathology
Humans
Male
Melphalan / therapeutic use
Neoplasm Metastasis
Podophyllotoxin / therapeutic use
Programmed Cell Death 1 Receptor / immunology
Remission Induction / methods*
Salvage Therapy

Substances

Antibodies, Monoclonal, Humanized
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Cytarabine
pembrolizumab
Podophyllotoxin
Melphalan
Carmustine

Supplementary concepts

BEAM protocol